ABVD, the Stanford V Regimen, and BEACOPP for Hodgkin's Lymphoma: What Should an Oncologist Do?
- 1 June 2005
- journal article
- comment
- Published by Elsevier BV in Clinical Lymphoma
- Vol. 6 (1), 50-51
- https://doi.org/10.3816/clm.2005.n.028
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's DiseaseThe New England Journal of Medicine, 2003
- Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup TrialJournal of Clinical Oncology, 2003
- A Prognostic Score for Advanced Hodgkin's DiseaseThe New England Journal of Medicine, 1998
- Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.Journal of Clinical Oncology, 1995
- Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVDThe New England Journal of Medicine, 1992
- Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPPCancer, 1975